FDA Approves Second Cholesterol-Lowering PCSK9 Inhibitor.
The FDA approved Amgen’s Repatha (evolocumab), the second in a new class of cholesterol-lowering drugs called PCSK9 inhibitors. Repatha, which will cost $14,100 annually, is intended for patients with extremely high cholesterol levels and those with heart disease who cannot sufficiently lower their cholesterol levels with statins
להמשך קריאה
Novo Nordisk Will Not Seek Expanded Indication For T1D Drug.
Novo Nordisk announced it will not seek an expanded indication for Victoza as an add-on treatment to insulin for type 1 diabetes because of disappointing phase III Adjunct One trial where the rate of severe hypoglycemia was not significantly different for the treatment and placebo groups.
להמשך קריאה
FDA Approves Female Libido Treatment.
The FDA approved Addyi (flibanserin), a drug that works in a woman’s brain to solve a chemical imbalance among three neurotransmitters that impact sexual desire. The drug, which is designed to treat pre-menopausal women, is the first approved to boost female libido. Sprout Pharmaceutical believes the drug could be prescribed for as many as 10 percent of women and will be available in mid-October.
להמשך קריאה
Israel Company Seeks FDA Approval Of Ear-Clip Glucose Monitoring Device.
Israel-based medical device manufacturer Integrity Applications has begun the process with the FDA to bring its noninvasive glucose monitoring device, GlucoTrack, to the United States. The device clips on to the ear and allows users to monitor their blood glucose level without drawing blood.
להמשך קריאה
Novo Nordisk May Build Diabetes Drug Plant In US.
Danish drugmaker Novo Nordisk is considering building a factory in North Carolina to make an oral version of a medicine for type 2 diabetes called semaglutide.
להמשך קריאה
New Analysis of LIBRA Trial Published.
Victoza over 48 weeks induced a paradoxical increase in post challenge glucagon in T2DM at 12 weeks post treatment according to a new analysis of LIBRA trial in JCEM.
להמשך קריאה
Ubc9 Enzyme A Potent Negative Regulator Of Energy Storage In Human Fat Cells.
Ubc9 enzyme a potent negative regulator of energy storage in human fat cells may be a promising therapeutic target IN T2DM. The enzyme inhibits the genetic program that makes white adipocytes act more like thermogenic, fat-burning brown adipocytes להמשך קריאה
Gynecomastia In Pubertal Boys Tied To Increased IGF-1, Younger Age At Peak Height Velocity
Increased levels of IGF-1 and younger age at peak height velocity appear to be associated with gynecomastia in pubertal boys, according to a study in JCEM which evaluated 106 healthy boys aged five to 16 years, and also found that changes in ratio of estrogen to testosterone do not appear to be related to the condition
להמשך קריאה
Delayed Release Metformin Delivered In Lower Bowel Results In Fasting Plasma Glucose Reductions Without Increased Risk Of Adverse Events.
Delayed release metformin (Met DR), engineered to be delivered in the lower bowel, allowed patients to ingest a lower dose of the drug, and experience equivalent fasting plasma glucose control, compared with patients taking extended release formulations, according to phase II study in Diabetes Care.
להמשך קריאה
Nikola Tesla (10 July 1856 – 7 January 1943) was a Serbian American inventor, electrical engineer, mechanical engineer, physicist, and futurist best known for his contributions to the modern alternating current (AC) electricity system. In 1882, Tesla began working for the Continental Edison Company in France and in June 1884 he relocated to New York City where he was hired by Thomas Edison to completely redesign the Edison Company’s direct current generators. According to Tesla, Edison remarked, “There’s fifty thousand dollars in it for you – if you can do it. After months of work, Tesla fulfilled the task and inquired about payment. Edison, saying that he was only joking, replied, “Tesla, you don’t understand our American humor”. Instead, Edison offered a US$10 a week raise over Tesla’s US$18 per week salary; Tesla refused the offer and immediately resigned. After leaving Edison’s company Tesla partnered with two businessmen in 1886 who agreed to finance an electric lighting company in Tesla’s name, Tesla Electric Light & Manufacturing. The company installed electrical arc light based illumination systems designed by Tesla and also had designs for dynamo electric machine commutators, the first patents issued to Tesla in the US. Soon the investors lost interest in Tesla’s ideas and forced Tesla out leaving him penniless. He had to work at various electrical repair jobs and even as a ditch digger for $2 per day. In late 1886 Tesla met a Western Union superintendent that based on Tesla’s patents agreed to back him financially. Together in April 1887 they formed the Tesla Electric Company with an agreement that profits from generated patents would go 1/3 to Tesla, 1/3 to Peck and Brown, and 1/3 to fund development. One of the things Tesla developed in 1887 was an induction motor that ran on alternating current. Engineers working for the Westinghouse Electric & Manufacturing Company reported to George Westinghouse that Tesla had a viable AC motor and related power system. Tesla’s demonstration of his induction motor and Westinghouse’s subsequent licensing of the patent, both in 1888, put Tesla firmly on the “AC” side of the so-called “War of Currents,” between Edison and Westinghouse. On 30 July 1891, at the age of 35, Tesla became a naturalized citizen of the United States, and established his South Fifth Avenue laboratory, and later another at 46 E. Houston Street, in New York. He lit electric lamps wirelessly at both locations, demonstrating the potential of wireless power transmission. In the same year, he patented the Tesla coil. In 1893, George Westinghouse won the bid to light the 1893 World’s Columbian Exposition in Chicago with alternating current, beating out a General Electric bid by one million dollars. This World’s Fair devoted a building to electrical exhibits. It was a key event in the history of AC power, as Westinghouse demonstrated the safety, reliability, and efficiency of the “Tesla Polyphase System”. In 1895 Tesla may have inadvertently captured an X-ray image (predating Wilhelm Röntgen’s December 1895 discovery) when he tried to photograph Mark Twain illuminated by a Geissler tube. The only thing captured was the metal locking screw on the camera lens. Tesla proceeded to do his own experiments in X-ray imaging, developing a high energy single terminal vacuum tube that worked from the output of the Tesla Coil. Tesla held that the “instrument will enable one to generate Roentgen rays of much greater power than obtainable with ordinary apparatus”. Tesla went on to pursue his ideas of wireless lighting and electricity. In 1898, he demonstrated a radio-controlled boat to the public during an electrical exhibition at Madison Square Garden. The crowd that witnessed the demonstration made outrageous claims about the workings of the boat, such as magic, telepathy, and being piloted by a trained monkey hidden inside. Tesla tried to sell his idea to the U.S. military as a type of radio-controlled torpedo, but they showed little interest. Tesla was renowned for his achievements and showmanship, eventually earning him a reputation of an archetypal “mad scientist”. His patents earned him a considerable amount of money but he lived most of his life in a series of New York hotels, through his retirement. The 1915 Nobel Prize in Physics was offered to Thomas Edison and Nikola Tesla; but there was a claim that neither was given the award because of their animosity toward each other. Tesla never married and died at age 86, alone in room 3327 of the New Yorker Hotel. His work fell into relative obscurity after his death, but in 1960 the General Conference on Weights and Measures named the SI unit of magnetic flux density “the Tesla” in his honor. 